{"id":"W2595988118","doi":"10.1182/blood.v128.22.4632.4632","title":"Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont; Université de Montréal; Leukemia & Lymphoma Society of Canada; University of British Columbia; McGill University Health Centre; Saint John Regional Hospital; Ottawa Hospital; Saskatchewan Cancer Agency; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Melphalan; Minimal residual disease; Lenalidomide; Busulfan; Multiple myeloma; Internal medicine; Maintenance therapy; Autologous stem-cell transplantation; Oncology; Thalidomide; Surgery; Urology; Bone marrow; Transplantation; Hematopoietic stem cell transplantation; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001639961,0.0005833196,0.001004495,0.0003195358,0.00072707,0.0007141751,0.0005837673,0.0004291088,0.002660934],"category_scores_gemma":[0.0007099687,0.0002487037,0.0006016085,0.0005638532,0.0005038024,0.0002329365,0.000214381,0.00124317,0.0003632636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.008668943,"about_ca_system_score_gemma":0.0089382,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.2458001,"about_ca_topic_score_gemma":0.5325981,"domain_scores_codex":[0.9995587,0.0001361167,0.00001479086,0.00006066,0.0001297179,0.00009987172],"domain_scores_gemma":[0.9991035,0.00007123728,0.0001199764,0.00004949525,0.0001363204,0.0005194723],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4360077,0.02521896,0.10752,0.0007656139,0.00295458,0.0005458248,0.0005895513,0.00749742,0.04422076,0.0009652429,0.03712953,0.3365848],"study_design_scores_gemma":[0.1106897,0.2820515,0.5253771,0.0001959378,0.001977642,0.001118303,0.000209372,0.005069911,0.01186037,0.000418375,0.06093386,0.00009800621],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9817971,0.004173365,0.0003589274,0.001321504,0.0001201165,0.001309216,0.005256531,0.00008130817,0.005582],"genre_scores_gemma":[0.9830852,0.001978922,0.001927614,0.001079701,0.0000966016,0.0003007311,0.005692254,0.00002804035,0.005811024],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2458001,"threshold_uncertainty_score":0.4887388,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0451543149474045,"score_gpt":0.3399590849051596,"score_spread":0.2948047699577551,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}